Dolutegravir (DTG) is the only second-generation integrase inhibitor (INI) available in clinical practice. !It has potential advantages in comparison to first-generation INIs including unboosted daily dosing, limited cross resistance, and a high barrier to resistance. !In clinical trials DTG proved its efficacy and safety in both naïve and experienced patients. !However, data on efficacy in clinical practice are still lacking.
Efficacy of Dolutegravir-based combination antiretroviral therapy in clinical practice in Italy and Wales: result from a multicenter, international study.
Nunnari G;Pellicanò G;
2016-01-01
Abstract
Dolutegravir (DTG) is the only second-generation integrase inhibitor (INI) available in clinical practice. !It has potential advantages in comparison to first-generation INIs including unboosted daily dosing, limited cross resistance, and a high barrier to resistance. !In clinical trials DTG proved its efficacy and safety in both naïve and experienced patients. !However, data on efficacy in clinical practice are still lacking.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
